Accelerated Approval Does Not Speed Oncologics To Market, Study Finds
This article was originally published in RPM Report
Executive Summary
Development time is the same for cancer drugs cleared under subpart H and under the regular approval pathway, according to a study in the Journal of Clinical Oncology. Article calls attention to idea that cancer drugs may need new, more favorable FDA policies on surrogate markers.